title: Osteosarcoma metastasis: prospective role of ezrin.
abstract: Osteosarcoma is the most commonly diagnosed primary malignant bone tumor, with similar global incidence rate across childhood and adolescence. Patients with localized disease have a 5-year survival period of 80 %; however, the prognosis is poor in those with metastatic osteosarcoma. The origin of the primary tumor is most frequently the metaphyseal (actively growing) regions of the distal femur, proximal tibia, and proximal humerus, although the tumor can develop in any bone, and the most likely sites for metastasis are the lungs and bone. Ezrin is a member of the ezrin-radixin-moesin (ERM) family of proteins that functions as a cross-linker between the actin cytoskeleton and the plasma membrane, and ezrin also plays a positive role in maintaining cell shape and polarity and facilitates membrane-trafficking pathways, cell migration, cell signaling, growth regulation, and differentiation. There is strong evidence to suggest that ezrin is necessary for osteosarcoma metastasis. The objective of the current review is to summarize the know-how about metastatic progression in osteosarcoma, with a focus on ezrin. Despite the promise that preliminary studies on ezrin have shown, there is a great need to further analyze the role of ezrin in osteosarcoma metastasis and to determine its usefulness as a biomarker for the disease.
authors.affiliation: Department of Orthopedics, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, No. 141 Tianjin Road, Huangshi City, 435000, Hubei Province, China, yjz_hsch@163.com.
authors.forename: Yuanjin
authors.initials: Y
authors.lastname: Zhang
authors.forename: Ling
authors.initials: L
authors.lastname: Zhang
authors.forename: Guofu
authors.initials: G
authors.lastname: Zhang
authors.forename: Songbai
authors.initials: S
authors.lastname: Li
authors.forename: Jun
authors.initials: J
authors.lastname: Duan
authors.forename: Jie
authors.initials: J
authors.lastname: Cheng
authors.forename: Guozhen
authors.initials: G
authors.lastname: Ding
authors.forename: Chibing
authors.initials: C
authors.lastname: Zhou
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.forename: Pengcheng
authors.initials: P
authors.lastname: Luo
authors.forename: Dongbing
authors.initials: D
authors.lastname: Cai
authors.forename: Lianghong
authors.initials: L
authors.lastname: Kuang
authors.forename: Yichun
authors.initials: Y
authors.lastname: Zhou
authors.forename: Liqun
authors.initials: L
authors.lastname: Tong
authors.forename: Xiangdong
authors.initials: X
authors.lastname: Yu
authors.forename: Lifang
authors.initials: L
authors.lastname: Zhang
authors.forename: Lijun
authors.initials: L
authors.lastname: Xu
authors.forename: Li
authors.initials: L
authors.lastname: Yu
authors.forename: Xiaomei
authors.initials: X
authors.lastname: Shi
authors.forename: Aihong
authors.initials: A
authors.lastname: Ke
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000473:pathology*; D003598:Cytoskeletal Proteins / Q000502:physiology*; D006801:Humans; D018960:Hyaluronan Receptors / Q000502:physiology; D020935:MAP Kinase Signaling System / Q000502:physiology; D012516:Osteosarcoma / Q000556:secondary*; D051057:Proto-Oncogene Proteins c-akt / Q000502:physiology; D000099149:Ezrin
chemical_list: D003598:Cytoskeletal Proteins; D018960:Hyaluronan Receptors; D051057:Proto-Oncogene Proteins c-akt; D000099149:Ezrin